---
title: "Tolebrutinib"
date: 2021-08-31T18:13:08+0100
lastmod: 
author: Bruno Amaral
options:
  unlisted: false

description: 
categories: []
tags: []
layout: page

draft: true
enableDisqus : true
enableMathJax: false
disableToC: false
disableAutoCollapse: true
---

Based on the following article, this item was added to the Observatory page.

> Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Source [The Lancet](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00237-4/fulltext)


<div class="row">
<div class="col-md-10 mx-auto">

{{< metabase-embed dashboard="15" width="1300" height="1250" >}}

</div>
</div>